Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Characterization of Immune-Related Adverse Events of Ipilimumab Versus Placebo in mCRPC

April 29, 2014
By Tomasz Beer, MD, FACP
Video

Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.

Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.

Clinical Pearls:

  • Ipilimumab is an immune modulator that works by breaking tolerance and stimulating the immune system so that it can recognize and attack the prostate cancer
  • Since ipilimumab is not specific to a cancer antigen, it causes side effects that are related to an overactive immune system
  • The analysis of the trial found that the side effect profile of ipilimumab in prostate cancer is similar to what was previously described in melanoma, where the drug is approved
  • Standard approaches to the management of these side effects are almost always effective

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Jordyn Sava
June 12th 2025
Article

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Read More


Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Jordyn Sava;Yu Fujiwara, MD
August 1st 2024
Podcast

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Listen


Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Jordyn Sava
June 11th 2025
Article

Read More


Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen


Advancing Head and Neck Cancer Treatment: Insights From KEYNOTE-689

Advancing Head and Neck Cancer Treatment: Insights From KEYNOTE-689

Sabrina Serani
June 10th 2025
Article

The KEYNOTE-689 study showed pembrolizumab with standard of care significantly improved outcomes for resectable HNSCC, reducing recurrence or death by 27%.

Read More


OS Therapies Seeks FDA RMAT Status for OST-HER2 in Pediatric Osteosarcoma

OS Therapies Seeks FDA RMAT Status for OST-HER2 in Pediatric Osteosarcoma

Jordyn Sava
June 10th 2025
Article

Read More

Related Content

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Jordyn Sava
June 12th 2025
Article

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Read More


Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Jordyn Sava;Yu Fujiwara, MD
August 1st 2024
Podcast

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Listen


Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Jordyn Sava
June 11th 2025
Article

Read More


Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen


Advancing Head and Neck Cancer Treatment: Insights From KEYNOTE-689

Advancing Head and Neck Cancer Treatment: Insights From KEYNOTE-689

Sabrina Serani
June 10th 2025
Article

The KEYNOTE-689 study showed pembrolizumab with standard of care significantly improved outcomes for resectable HNSCC, reducing recurrence or death by 27%.

Read More


OS Therapies Seeks FDA RMAT Status for OST-HER2 in Pediatric Osteosarcoma

OS Therapies Seeks FDA RMAT Status for OST-HER2 in Pediatric Osteosarcoma

Jordyn Sava
June 10th 2025
Article

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.